Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib

Fig. 4

The dose reduction factor of a nonexclusive combination was calculated for a hypothetical drug combination with constant drug concentration profiles (C(t) for either drug). The best achievable dose reduction factor was calculated for five different drug combinations using a reasonable effect target of 0.1 and is shown on the right–hand side of the figure

Back to article page